An observational study in Primary Liver Cancer, sponsored by Huilian Zhu. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-09-29.
Sponsored by Huilian Zhu · Observational
This longitudinal observational cohort study was designed to investigate factors that influencing the occurrence and long-term survival of patients with primary liver cancer. Basic informations and detailed diagnosis informations (AJCC/TNM stage, MELD score, Child-Pugh score, and BCLC stage) were collected by professional doctors. Clinical outcomes (death, recurrence, and metastasis) will be followed up every two years after therapy.
Primary liver cancer (PLC) is highly malignant with high mortality which is particularly popular in China. Many factors are believed to associate with the occurrence and prognosis of liver cancer. This longitudinal observational cohort study was designed to investigate factors that influencing the occurrence and long-term survival of patients with primary liver cancer.
3,648 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,061 are open to participants now.
This study's planned enrollment of 4,000 is above the median of 200 across 850 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Huilian Zhu is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients of this study were invited from Sun Yat-sen University Cancer Center as soon as they were diagnosed as primary liver cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Time of Death
The exact death time of each participants will be checked in the government medical records system
Time frame: Up to 10 years
Time of recurrence
Time of recurrence will be obtained by telephone interview or medical treatment records
Time frame: From date of diagnosis until the date of cancer recurrence or date of death from any cause, whichever came first, assessed up to 10 years
Time of metastasis
Time of metastasis will be obtained by telephone interview or medical treatment records
Time frame: From date of diagnosis until the date of cancer metastasis or date of death from any cause, whichever came first, assessed up to 10 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huilian Zhu